Top Analyst Upgrades and Downgrades: BioMarin, Family Dollar, Lululemon, SunTrust and More

It is Monday and 24/7 Wall St. has seen many new analyst research calls that have to be covered. The bull market is on, with stocks having hit new highs on Friday, but investors and traders keep hearing that this is now a stock picker’s market rather than a raging bull market. We review dozens of analyst research reports each morning of the week in order to find new ideas and hidden gems for our readers. Some analyst reports cover stocks to buy, but some of them cover stocks to sell or to avoid.

These are this Monday’s top Wall Street analyst upgrades, downgrades and initiations.

Anixter International Inc. (NYSE: AXE) was downgraded to Neutral from Outperform at R.W. Baird.

Arcos Dorados Holdings Inc. (NYSE: ARCO) was raised to Buy from Underperform and given a $14.16 price target (versus a $9.61 close) at Bank of America Merrill Lynch.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was raised to Outperform from Neutral with a $73 price target (versus a $61.74 close) by Credit Suisse.

ALSO READ: Apple’s New Target Prices After the Split

Capital One Financial Corp. (NYSE: COF) was raised to Buy from Neutral at Nomura Securities.

Dollar General Corp. (NYSE: DG) was raised to Buy from Hold with a $75 price target (versus a $57.98 close) at Jefferies.

ALSO READ: Five Analyst Stocks With Over 100% Implied Upside

Enerplus Corp. (NYSE: ERF) was downgraded to Sector Perform from Outperform at RBC Capital Markets.

Family Dollar Stores Inc. (NYSE: FDO) was raised to Buy from Hold with a $79 price target (versus a $60.53 close) at Jefferies. Sterne Agee maintained a Neutral rating despite the Carl Icahn stake disclosure of 9.4%.